Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy

Patients with cancer frequently receive immune-checkpoint inhibitors (ICIs), which may modulate immune responses to COVID-19 vaccines. Recently, cytokine release syndrome (CRS) was observed in a patient with cancer who received BTN162b2 vaccination under ICI treatment. Here, we analyzed adverse even...

Descripción completa

Detalles Bibliográficos
Autores principales: Walle, Thomas, Bajaj, Sunanjay, Kraske, Joscha A., Rösner, Thomas, Cussigh, Christiane S., Kälber, Katharina A., Müller, Lisa Jasmin, Strobel, Sophia Boyoung, Burghaus, Jana, Kallenberger, Stefan M., Stein-Thöringer, Christoph K., Jenzer, Maximilian, Schubert, Antonia, Kahle, Steffen, Williams, Anja, Hoyler, Birgit, Zielske, Lin, Skatula, Renate, Sawall, Stefanie, Leber, Mathias F., Kunes, Russell Z., Krisam, Johannes, Fremd, Carlo, Schneeweiss, Andreas, Krauss, Jürgen, Apostolidis, Leonidas, Berger, Anne Katrin, Haag, Georg M., Zschäbitz, Stefanie, Halama, Niels, Springfeld, Christoph, Kirsten, Romy, Hassel, Jessica C., Jäger, Dirk, Ungerechts, Guy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499865/
https://www.ncbi.nlm.nih.gov/pubmed/35715501
http://dx.doi.org/10.1038/s43018-022-00398-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499865/
https://www.ncbi.nlm.nih.gov/pubmed/35715501
http://dx.doi.org/10.1038/s43018-022-00398-7

Ejemplares similares